Could it be that the results for those initial 12 were cherry picked and that the rest of the trial is not going so well? Could explain the dead silence from the company.
Or perhaps they aren’t enrolling as fast as anticipated. For this phase they want patients at a very specific stage within the disease progression, so perhaps it’s taking a bit longer to enroll those specific types of patients?
Don’t know, just throwing my dark thoughts out there.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.